New england journal of medicine publishes positive results from insmed's pivotal phase 3 aspen study of brensocatib in patients with bronchiectasis

—largest global clinical trial ever conducted in bronchiectasis demonstrates statistically significant and clinically meaningful reduction in frequency of pulmonary exacerbations versus placebo— —brensocatib 25 mg is the first investigational therapy for bronchiectasis to show a statistically significant reduction in the rate of lung function decline— —brensocatib is currently under priority review with the u.s. food and drug administration— bridgewater, n.j. , april 23, 2025 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 aspen study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the new england journal of medicine (nejm).
INSM Ratings Summary
INSM Quant Ranking